Benefit of aggressive lipid-lowering therapy: Insights from the post coronary artery bypass graft study and other trials

American Journal of Medicine

Volumn 105, Issue 1 A, 1998, Pages 63S-68S

  White, Carl W ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN;

CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY RISK; DRUG EFFICACY; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR; RISK MANAGEMENT; SECONDARY PREVENTION;

EID: 0032490707     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00214-9     Document Type: Conference Paper

References (20)

1. Verschuren W.M., Jacobs D.R., Bloemberg B.P.M., et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures twenty-five-year follow-up of the Seven Countries Study . JAMA. 274:1995;131-136.
2. Kannel W.B. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 76:1995;69C-77C.
3. Kannel W.B., Castelli W.P., Gordon T. Cholesterol in the prediction of atherosclerotic disease new perspectives based on the Framingham Study . Ann Intern Med. 90:1979;85-91.
4. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med. 148:1988;36-69.
5. Ornish D., Brown S.E., Scherwitz L.W., et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 336:1990;129-153.
6. Schuler G., Hambrecht R., Schlierf G., et al. Regular physical exercise and low-fat diet effects on progression of coronary artery disease . Circulation. 86:1992;1-11.
7. Watts G.F., Lewis B., Brunt J.N.H., et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 339:1992;563-569.
8. Effect of simvastatin on coronary atheroma the Multicentre Anti-Atheroma Study (MAAS) . Lancet. 344:1994;633-638.
9. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
10. Waters D., Higginson L., Gladstone P., et al. Effects of monotherapy with an HMG-CoA reductase inhibitor upon the progression of coronary atherosclerosis as assessed by serial quantitative arteriography the Canadian Coronary Atherosclerosis Intervention Trial . Circulation. 89:1994;959-968.
11. Jukema J.W., Bruschke A.V.G., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels the Regression Growth Evaluation Statin Study (REGRESS) . Circulation. 91:1995;2528-2540.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
13. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 345:1995;1274-1275.
14. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
15. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol. 76:(suppl):1995;10C-17C.
16. Rossouw J.E. Lipid-lowering interventions in angiographic trials. Am J Cardiol. 76:(suppl):1995;86C-92C.
17. Sacks F.M., Gibson C.M., Rosner B., et al. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Am J Cardiol. 76:(suppl):1995;78C-85C.
18. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 336:1997;153-162.
19. Rossouw J.E., Lewis B., Rifkind B.M. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 323:1990;1112-1119.
20. Rossouw J.E., Canner P.L., Hulley S.B. Deaths from injury, violence, and suicide in secondary prevention trials of cholesterol lowering. (Letter) N Engl J Med. 325:1991;1813.